TSE:SIS

Savaria Corp (SIS.TO)

29.22
+0.42 (1.46%)
as of Jun 26, 2026, 8:00:01 pm Market Open.
306 watching
0
Investor Insights
star iconJun 26, 2026, 12:00 am

This summary was created by AI, based on 6 opinions in the last 12 months.

Savaria Corp (SIS-T) has garnered attention from various experts due to its favorable market positioning and growth potential, particularly in the accessibility industry. The company's strategic shift toward European markets and its focus on U.S.-based production have helped mitigate the impact of previous tariff challenges. Analysts note that Savaria's products are largely FDA-regulated, making them compliant with CUSMA regulations, which is a significant advantage. With an aging population increasingly inclined to age at home, the demand for Savaria's offerings appears robust. Additionally, cost reduction strategies and product innovation are seen as key drivers for future growth, making it a compelling long-term investment with a current yield of 2.69% and a price target of $24.44.

consensus icon
Consensus
Positive
valuation icon
Valuation
Fair Value
review icon
Similar
Invacare, IVC
BUY

Owns a lot. Is happy with this small-cap. The recent choppiness is due to the founder selling shares, but SIS is in a good spot. They guided margins from 15% to 20% and are already almost there. They're in a demographic sweet spot. Are expanding revenues. Will raise the dividend, which is already good.

PARTIAL BUY

Impressed with business. Very steady revenue lines. Elevators and stair lift demand growing. Growth not high, but is a quality company. 

PAST TOP PICK
(A Top Pick Sep 25/23, Up 52%)

Has owned this for a long time, since it was $5. Are the global leader in this space. Results this year are phenomenal with strong organic growth and increasing profit margins. Are becoming synergistic in their various businesses across US and Europe through cross-selling. Are reaching 19% EBITDA margins from supply chain optimization. Now, it's hitting all-time highs, but is a good long-term investment due to an aging population as people buy stairlifts and elevators. A lot of growth, top and bottom, ahead. Today, the chairman is selling shares, which doesn't scare him, because it doesn't change the fundamentals.

HOLD

It has good fundamentals and he likes it. Management is looking to increase the dividend and is moving along faster than expected. In general you should continue to hold good companies with good fundamentals through downturns and maybe buy more.

premiumPremium content

It's a Monthly Gems opinion which is available only for Stockchase Premium

Curated by Allan Tong since 2019.
99+ opinions with 4.15 rating.

TOP PICK

Quietly rising 17% since the year started, this Quebec manufacturer of in-home lifts serves an aging demographic. One thing to note is its EPS growth: up 8.1% annually since 2021. In the last year, revenue grew 2.2% to $835 million. Insider have been buying shares (always a good sign) and now hold 20% of the company. The icing on the cake is SIS' dividend, which has more than doubled in the past decade and now pays just under 3%. This trend should continue, based on management projections of revenue growth to top $1 billion next year. Last year, the company enjoyed a record backlog as well.

TOP PICK

Very well run company that has respect for shareholders. Long term tailwinds with home elevator service. Aging population will continue demand for products. Recent tour of Canadian factory very impressive. Expecting further dividend increases in 2025. Expecting further growth. 

BUY

It is the only consumer discretionary stock they own. She considers it a staple since it provides accessibility equipment to keep people in their homes longer, which they want. Also vertical housing is on the rise in a city like Toronto and there are townhouses now being built with elevator shafts which is part of their business.

TOP PICK

It is a global leader in home accessibility equipment and patient handling. A concern in the second quarter report gave the stock a hit but he considers it a one-time event. Also it did a recent equity issue which is being used to pay down debt. It has good management, strong organic sales growth. a good backlog and improving margins. It should be able to make good acquisitions. Trades at 9X EBITDA, near historical lows.  
Buy 8  Hold 0  Sell 0

(Analysts’ price target is $20.71)
PAST TOP PICK
(A Top Pick Jun 06/22, Up 18%)

Great Q1 results. Strong organic growth, margins improved, record backlog for the rest of the year. 10x EBITDA, very reasonable. Good demographics. Targeting $1B in sales by 2025, tremendous upside if they can reach that goal. A better play than cost-intensive LTC homes. Yield is 3.1%.

BUY
Allan Tong’s Discover Picks

Savaria’s revenues have grown from $120 million in 2016 to $661 million in 2021 (the last reported full year). Accordingly, operating income has also climbed from $18.19 million to $49.18 million in the same time frame. However, the same cannot be said of net income, which was $12.3 million in 2016, then topped $26.46 million in 2020 but then fell to $11.54 million in 2021. Read: Canadian Tire, Savaria & XLI

HOLD

Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. Stay at home trends support business. Stable fundamentals with growth expected. Debt trending lower. Higher valuation historically. Unlock Premium - Try 5i Free

BUY
Historically, it's done very well by growing by acquisition and organically. We're seeing ramp-up in demand from aging baby boomers that will push demand for Savaria's products. They pay a nice, growing dividend. It trades at a decent valuation. Their last quarter was good. But it's a small-cap company so prone to volatility.
BUY

Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. Solid cash flow profile. Industry tailwinds strong. Diversified geographically and product line. Improved valuations. Unlock Premium - Try 5i Free

HOLD

Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. Missed quarterly projections. Price increases just went into effect. Volume backlog in Toronto 3x last year. Margin expansion a goal. Unlock Premium - Try 5i Free

STRONG BUY
World's largest in home accessibility and patient handling. Aging demographic tailwinds. Very well managed. Margin compression from supply chain issues. Anticipates good execution. Business is booming.
Showing 16 to 30 of 126 entries